GLP-1 Digest

GLP-1 Digest

Home
Archive
Leaderboard
About
Why Novo Nordisk is Out of Options (Except One)
patents become weapons
 • 
Ashwin Sharma, MD
18
Error
Are GLP-1s About to Kill the Alcohol Industry?
Change is definitely coming, but not in the way you think
 • 
Ashwin Sharma, MD
Error
GLP-1s Are Quietly Killing Your Cravings (and Maybe Your Bad Habits Too)
New brain-imaging studies reveal these meds may silence the impulse engine driving addiction, compulsive behaviours, and billion-dollar snack aisles
 • 
Ashwin Sharma, MD
7
Error
Hims Has No Way Out of Their $725 Million Hole
Compounding's banned. No branded alternatives. Patent reality bites.
 • 
Ashwin Sharma, MD
2
Error
How GLP-1s Are Breaking Life Insurance
Patients look healthy on paper. Two years later, they're high-risk again.
 • 
Ashwin Sharma, MD
33
Error
Why Novo Nordisk Won't Beat Eli Lilly
Dividends over R&D is not a good strategy
 • 
Ashwin Sharma, MD
Error
How a Tiny British Startup Became Silicon Valley's Hottest Acquisition
Tiny British startup? Hottest? How?
 • 
Ashwin Sharma, MD
Error
GLP-1 Digest
GLP-1 Digest
The GLP-1 newsletter for founders, operators and investors.
Recommendations
In-Network
In-Network
David Ohta

GLP-1 Digest

AboutArchiveRecommendationsSitemap
© 2025 Ashwin Sharma
Privacy ∙ Terms ∙ Collection notice
Start writingGet the app
Substack is the home for great culture
ErrorError